Keywords: Seattle Genetics, Lintuzumab, Fails endpoint, Myeloid leukemia, Brentuximab

Seattle Genetics drops leukemia drug lintuzumab as it fails to meet Ph IIb primary endpoint

Article | 14 September 2010

Print This

Shares of US biotech firm Seattle Genetics (Nasdaq: SGEN) fell 4.5% to $12.15in morning trading, after the company announced that its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in